But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

is to work with Qualcomm to 'digitally upgrade' its Respimat inhaler, introducing a new connectivity solution to improve medication adherence in chronic obstructive pulmonary disorder (COPD ...

The Hailie Smartinhaler device has also been cleared for use with inhalers from other ... to patients with asthma and COPD under a 510(k) over-the-counter clearance. In a statement, the company ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).

Part B medication coverage is limited to drugs administered ... and thus warrant early consideration in elderly patients with COPD.